Abbott Named to Science Magazine's List of Top Employers

AbbottFor the fifth consecutive year, Abbott (NYSE: ABT) has been named among the top 20 employers in the Science magazine 2007 Top Biotech and Pharma Employer's survey.

Science is at the center of Abbott's broad base of businesses. To enhance the experience for researchers, Abbott offers an array of development opportunities in the areas of leadership and business skills, as well as collaborations with academia to help them be successful in the industry environment. Recently Abbott also was named one of the "Best Places to Launch a Career" by BusinessWeek magazine.

"Helping our scientists reach their full potential is critical to Abbott's continued success and to finding new and better treatment options for patients, so it's important that we foster an environment where our scientists and their innovative solutions can flourish," said Miles D. White, chairman and chief executive officer, Abbott. "In addition to again being honored for the kind of workplace we have created by Science magazine, the breakthrough work at Abbott has recently been recognized by Prix Galien USA, the Wall Street Journal Technology Awards and the Chicago Innovation Awards."

The Science magazine rankings are determined from a study conducted by an independent research firm commissioned by the journal, and appeared in a special business supplement of the Oct. 12 issue. Survey respondents were asked to rate companies based on 23 characteristics, including financial strength, easy adaptation to change and a research-driven environment.

The 2007 survey sought to identify the companies with the best reputations as employers, based on 3,157 survey responses from readers of Science and other selected respondents. Twenty-nine percent of the respondents came from outside the United States, primarily Western Europe, and 92 percent worked in private industry.

Survey responses were analyzed by Senn-Delaney Culture Diagnostics & Measurement, which used a mathematical process to assign a unique score to rate the companies' employer reputation, taking into account 23 different attributes including: Corporate Image, Leadership and Direction, Financial Prowess, Work Culture/Environment, Work/Life Balance, Academics and Collegial Exchange, and Compensation and Benefits.

Industry-Leading Development Opportunities
A number of unique development programs have been established for Abbott's scientists at all levels of the organization to help nurture and grow their skills in order to help them achieve success within the company. Leadership Development for Scientists, a program specifically designed to provide enhanced skills for high-potential scientists and physicians, helps develop leadership traits and business skills that are not usually included in a scientist's normal curriculum. Abbott also offers a Physician Development Program, which is designed to provide M.D.s who have never worked in industry with an overview of the drug development process. In addition, Abbott collaborates with top colleges and universities to develop curricula that will help scientists obtain a business background to work in industry. Through these proactive collaborations, Abbott helps ensure that the candidates it considers will have the appropriate backgrounds to achieve success in their positions.

Rewarding and Recognizing Innovative Ideas and Achievements
In addition to external honors, Abbott scientists are eligible for unique internal recognition. Induction into the prestigious Volwiler Society represents the highest honor an Abbott scientist can receive. Employees also are eligible for President's Awards, patent/inventor awards and several others.

About Abbott
In addition to the recognition in Science magazine, Abbott has been named among the country's best employers for scientists by The Scientist magazine. The company was recently named one of the "Best Places to Launch a Career" by BusinessWeek magazine and Working Mother magazine's "Top 100 Best Companies for Working Mothers" list. Abbott also has been included on DiversityInc magazine's list of the "Top 50 Companies for Diversity" for many years.

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

Most Popular Now

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...